VLI-02A

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameVLI-02A

Drug Alias NameAdCEA-CD40LAdCEApIX-CEA-pK7modified adenovirus recombinant vector vaccine (DNAtrix)modified adenovirus recombinant vector vaccine (VectorLogics)dual CD40 costimulator/CEA antigen (adenoviral vector vaccine) (VectorLogics) +[6]

ClassificationVaccines > Development/production technology > Recombinant vector vaccineVaccines > Application > Therapeutic vaccine

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 modulatorsTumor necrosis factor receptor superfamily member 5 agonists

TargetsCarcinoembryonic antigen related cell adhesion molecule 5Tumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesVectorlogics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesVectorlogics

Active IndicationsN/A

Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A